Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp.TNXP · Entity 6169 | Chief Financial Officer | June 30, 2026 | July 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tonix Pharmaceuticals Holding Corp.
Report date June 30, 2026 · Filed July 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par valueSEC Table I · non-derivative | Direct | 2,154 |
Reported balance
After 2026-06-30 transaction · row 1
1 source rowRow 1 · 2026-06-30 · Other · Acquired 1,453 · Balance 2,154 F1: Shares acquired through the Tonix Pharmaceuticals Holding Corp. 2025 Employee Stock Purchase Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares acquired through the Tonix Pharmaceuticals Holding Corp. 2025 Employee Stock Purchase Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2026 Filed Jul 9, 2026 13:05 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | OtherCommon Stock, $0.001 par value | 1,453 | $10.91 | $15,858.04 |
DisclosureSEC source: 0001493152-26-032615 · ownership.xml · nonDerivative · entry 1 SAENGER BRADLEY · CIK 0001668150 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,154 F1 · kind: Shares acquired through the Tonix Pharmaceuticals Holding Corp. 2025 Employee Stock Purchase Plan. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 12:03 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 39,011 | $0.00 Strike: $17.86 | $0.00 |
DisclosureSEC source: 0001999371-26-004388 · saenger-form4_022626.xml · derivative · entry 2 SAENGER BRADLEY · CIK 0001668150 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,011 Underlying: Common Stock · 39,011 shares Expires 2036-02-24 F2 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. F1 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/48th each month thereafter for 36 months. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 12:03 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 39,012 | $0.00 Strike: $14.29 | $0.00 |
DisclosureSEC source: 0001999371-26-004388 · saenger-form4_022626.xml · derivative · entry 1 SAENGER BRADLEY · CIK 0001668150 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,012 Underlying: Common Stock · 39,012 shares Expires 2036-02-24 F2 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. F1 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/48th each month thereafter for 36 months. Read SEC document |
| December 31, 2025 Filed Feb 17, 2026 12:00 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantCommon Stock, par value $0.001 | 701 | $13.42 | $9,407.42 |
DisclosureSEC source: 0001999371-26-003371 · saenger-form5_021626.xml · nonDerivative · entry 1 SAENGER BRADLEY · CIK 0001668150 · Chief Financial Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 701 F1 · kind: Shares acquired through the Tonix Pharmaceuticals Holding Corp. 2025 Employee Stock Purchase Plan. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 23:51 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 25,792 | $0.00 Strike: $10.06 | $0.00 |
DisclosureSEC source: 0001839882-25-011958 · saenger-form4_022725.xml · derivative · entry 3 SAENGER BRADLEY · CIK 0001668150 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,792 Underlying: Common Stock · 25,792 shares Expires 2035-02-25 F3 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F2 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 23:51 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 25,792 | $0.00 Strike: $8.05 | $0.00 |
DisclosureSEC source: 0001839882-25-011958 · saenger-form4_022725.xml · derivative · entry 2 SAENGER BRADLEY · CIK 0001668150 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,792 Underlying: Common Stock · 25,792 shares Expires 2035-02-25 F3 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F2 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| February 05, 2025 Filed Feb 27, 2025 23:51 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | OtherCommon Stock, par value $0.001 | 0.04 | $0.00 | $0.00 |
DisclosureSEC source: 0001839882-25-011958 · saenger-form4_022725.xml · nonDerivative · entry 1 SAENGER BRADLEY · CIK 0001668150 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Shares were surrendered without considerations following a reverse stock split of the Issuer's common stock. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 22:07 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 282,000 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001999371-24-002951 · saenger-form4_022724.xml · derivative · entry 2 SAENGER BRADLEY · CIK 0001668150 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 282,000 Underlying: Common Stock · 282,000 shares Expires 2034-02-27 F2 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F1 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 22:07 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 282,000 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001999371-24-002951 · saenger-form4_022724.xml · derivative · entry 1 SAENGER BRADLEY · CIK 0001668150 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 282,000 Underlying: Common Stock · 282,000 shares Expires 2034-02-27 F2 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F1 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| February 23, 2023 Filed Feb 24, 2023 23:37 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 200,000 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0001839882-23-004703 · ownership.xml · derivative · entry 2 SAENGER BRADLEY · CIK 0001668150 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-02-23 F2 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F1 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| February 23, 2023 Filed Feb 24, 2023 23:37 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 200,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001839882-23-004703 · ownership.xml · derivative · entry 1 SAENGER BRADLEY · CIK 0001668150 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-02-23 F2 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F1 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 22:19 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 900,000 | $0.00 Strike: $0.83 | $0.00 |
DisclosureSEC source: 0001387131-22-002107 · ownership.xml · derivative · entry 4 SAENGER BRADLEY · CIK 0001668150 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900,000 Underlying: Common Stock · 900,000 shares Expires 2032-02-15 F3 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F2 · derivative.exercise_date: 10% of the option vests on the first anniversary of issuance, 10% on the second anniversary of issuance, 40% on the third anniversary of issuance, and 40% on the fourth anniversary of issuance. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 22:19 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 900,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001387131-22-002107 · ownership.xml · derivative · entry 3 SAENGER BRADLEY · CIK 0001668150 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900,000 Underlying: Common Stock · 900,000 shares Expires 2032-02-15 F3 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F2 · derivative.exercise_date: 10% of the option vests on the first anniversary of issuance, 10% on the second anniversary of issuance, 40% on the third anniversary of issuance, and 40% on the fourth anniversary of issuance. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 22:19 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 900,000 | $0.00 Strike: $0.41 | $0.00 |
DisclosureSEC source: 0001387131-22-002107 · ownership.xml · derivative · entry 2 SAENGER BRADLEY · CIK 0001668150 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900,000 Underlying: Common Stock · 900,000 shares Expires 2032-02-15 F3 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F2 · derivative.exercise_date: 10% of the option vests on the first anniversary of issuance, 10% on the second anniversary of issuance, 40% on the third anniversary of issuance, and 40% on the fourth anniversary of issuance. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 22:19 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 900,000 | $0.00 Strike: $0.21 | $0.00 |
DisclosureSEC source: 0001387131-22-002107 · ownership.xml · derivative · entry 1 SAENGER BRADLEY · CIK 0001668150 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900,000 Underlying: Common Stock · 900,000 shares Expires 2032-02-15 F3 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F1 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| June 30, 2021 Filed Feb 11, 2022 22:18 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantCommon Stock, par value $0.001 | 18,248 | $0.58 | $10,583.84 |
DisclosureSEC source: 0001387131-22-001717 · ownership.xml · nonDerivative · entry 1 SAENGER BRADLEY · CIK 0001668150 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,645 F1 · date: Shares acquired through the Tonix Pharmaceuticals Holding Corp. 2020 Employee Stock Purchase Plan. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 22:52 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 540,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001387131-21-002888 · ownership.xml · derivative · entry 2 SAENGER BRADLEY · CIK 0001668150 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540,000 Underlying: Common Stock · 540,000 shares Expires 2031-02-23 F2 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F1 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 22:52 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 540,000 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001387131-21-002888 · ownership.xml · derivative · entry 1 SAENGER BRADLEY · CIK 0001668150 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540,000 Underlying: Common Stock · 540,000 shares Expires 2031-02-23 F2 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F1 · derivative.exercise_date: One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| May 04, 2020 Filed May 6, 2020 22:26 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 360,000 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001387131-20-004485 · ownership.xml · derivative · entry 2 SAENGER BRADLEY · CIK 0001668150 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,000 Underlying: Common Stock · 360,000 shares Expires 2030-05-04 F2 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F1 · derivative.exercise_date: The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| May 04, 2020 Filed May 6, 2020 22:26 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 360,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001387131-20-004485 · ownership.xml · derivative · entry 1 SAENGER BRADLEY · CIK 0001668150 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,000 Underlying: Common Stock · 360,000 shares Expires 2030-05-04 F2 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F1 · derivative.exercise_date: The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 21:24 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 24,000 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001387131-20-002257 · ownership.xml · derivative · entry 2 SAENGER BRADLEY · CIK 0001668150 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2030-02-25 F2 · price: The option was granted pursuant to the Issuer's 2020 Stock Incentive Plan. F1 · derivative.exercise_date: The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 21:24 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 24,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001387131-20-002257 · ownership.xml · derivative · entry 1 SAENGER BRADLEY · CIK 0001668150 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2030-02-25 F2 · price: The option was granted pursuant to the Issuer's 2020 Stock Incentive Plan. F1 · derivative.exercise_date: The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| January 06, 2020 Filed Feb 12, 2021 22:32 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantCommon Stock, par value $0.001 | 493 | $1.02 | $502.86 |
DisclosureSEC source: 0001387131-21-002306 · tnxp-form5_123120.xml · nonDerivative · entry 1 SAENGER BRADLEY · CIK 0001668150 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,397 F1 · date: Shares acquired through the Tonix Pharmaceuticals Holding Corp. 2019 Employee Stock Purchase Plan. Read SEC document |
| July 31, 2019 Filed Feb 14, 2020 21:14 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantCommon Stock, par value $0.001 | 815 | $11.82 | $9,633.30 |
DisclosureSEC source: 0001387131-20-001792 · saenger-form5_123119.xml · nonDerivative · entry 2 SAENGER BRADLEY · CIK 0001668150 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 904 F2 · date: Shares acquired through the Tonix Pharmaceuticals Holding Corp. 2019 Employee Stock Purchase Plan. Read SEC document |
| May 06, 2019 Filed May 8, 2019 12:00 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 28,835 | $0.00 Strike: $2.56 | $0.00 |
DisclosureSEC source: 0001387131-19-003426 · ownership.xml · derivative · entry 2 SAENGER BRADLEY · CIK 0001668150 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,835 Underlying: Common Stock · 28,835 shares Expires 2029-05-06 F2 · price: The option was granted pursuant to the Issuer's 2019 Stock Incentive Plan. F1 · derivative.exercise_date: The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| May 06, 2019 Filed May 8, 2019 12:00 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 28,835 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0001387131-19-003426 · ownership.xml · derivative · entry 1 SAENGER BRADLEY · CIK 0001668150 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,835 Underlying: Common Stock · 28,835 shares Expires 2029-05-06 F2 · price: The option was granted pursuant to the Issuer's 2019 Stock Incentive Plan. F1 · derivative.exercise_date: The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| February 26, 2019 Filed Feb 27, 2019 22:39 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 5,170 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001387131-19-001537 · form4-saenger_022619.xml · derivative · entry 2 SAENGER BRADLEY · CIK 0001668150 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,170 Underlying: Common Stock · 5,170 shares Expires 2029-02-25 F2 · price: The option was granted pursuant to the Issuer's 2018 Stock Incentive Plan. F1 · derivative.exercise_date: The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| February 26, 2019 Filed Feb 27, 2019 22:39 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 5,170 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001387131-19-001537 · form4-saenger_022619.xml · derivative · entry 1 SAENGER BRADLEY · CIK 0001668150 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,170 Underlying: Common Stock · 5,170 shares Expires 2029-02-25 F2 · price: The option was granted pursuant to the Issuer's 2018 Stock Incentive Plan. F1 · derivative.exercise_date: The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| February 17, 2019 Filed Feb 14, 2020 21:14 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantCommon Stock, par value $0.001 | 59 | $17.85 | $1,053.15 |
DisclosureSEC source: 0001387131-20-001792 · saenger-form5_123119.xml · nonDerivative · entry 1 SAENGER BRADLEY · CIK 0001668150 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 904 F1 · date: Shares acquired through the Tonix Pharmaceuticals Holding Corp. 2018 Employee Stock Purchase Plan. Read SEC document |
| June 14, 2018 Filed Jun 14, 2018 20:05 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, $0.001 par value | 300 | $4.10 | $1,230.00 |
DisclosureSEC source: 0001615774-18-005289 · s110839_form4.xml · nonDerivative · entry 1 SAENGER BRADLEY · CIK 0001668150 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,079 Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 21:08 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 39,150 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001615774-18-001262 · s109083_form4.xml · derivative · entry 2 SAENGER BRADLEY · CIK 0001668150 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,150 Underlying: Common Stock · 39,150 shares Expires 2028-02-12 F2 · price: The option was granted pursuant to the Issuer's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 21:08 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 39,150 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001615774-18-001262 · s109083_form4.xml · derivative · entry 1 SAENGER BRADLEY · CIK 0001668150 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,150 Underlying: Common Stock · 39,150 shares Expires 2028-02-12 F2 · price: The option was granted pursuant to the Issuer's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 02:22 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 47,500 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001615774-17-000858 · s105458_form4.xml · derivative · entry 2 SAENGER BRADLEY · CIK 0001668150 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,500 Underlying: Common Stock · 47,500 shares Expires 2027-03-01 F2 · price: The option was granted pursuant to the Issuer's 2016 Stock Incentive Plan. F3 · derivative.exercise_date: The option vests 50% if the Issuer achieves enrollment of 250 patients in its HONOR study by December 31, 2017, with the remaining 50% vesting 1% for each patient that is enrolled in the HONOR study by December 31, 2017 in excess of 250, subject to a one year minimum service period prior to vesting. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 02:22 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 47,500 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001615774-17-000858 · s105458_form4.xml · derivative · entry 1 SAENGER BRADLEY · CIK 0001668150 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,500 Underlying: Common Stock · 47,500 shares Expires 2027-03-01 F2 · price: The option was granted pursuant to the Issuer's 2016 Stock Incentive Plan. F1 · derivative.exercise_date: The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months. Read SEC document |
| June 30, 2016 Filed Feb 13, 2017 11:08 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | OtherCommon Stock | 3,296 | $1.74 | $5,735.04 |
DisclosureSEC source: 0001615774-17-000515 · s105311_form5.xml · nonDerivative · entry 1 SAENGER BRADLEY · CIK 0001668150 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,335 F1 · kind: Shares acquired through the Tonix Pharmaceuticals Holding Corp. Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.